NYSE:CHEChemed Stock Price, Forecast & News

Chemed's stock was trading at $414.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CHE shares have increased by 15.2% and is now trading at $477.16. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chemed.

Chemed is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Chemed.

Chemed Co. (NYSE:CHE) posted its earnings results on Tuesday, April, 28th. The company reported $3.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.65 by $0.03. The firm had revenue of $515.80 million for the quarter, compared to analyst estimates of $523.04 million. Chemed had a net margin of 11.60% and a return on equity of 35.99%. The firm's revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the company earned $2.92 EPS. View Chemed's earnings history.

Chemed declared a quarterly dividend on Tuesday, May 19th. Shareholders of record on Thursday, May 28th will be given a dividend of $0.32 per share on Wednesday, June 17th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date of this dividend is Wednesday, May 27th. View Chemed's dividend history.

4 analysts have issued 12 month target prices for Chemed's stock. Their forecasts range from $490.00 to $535.00. On average, they expect Chemed's share price to reach $515.00 in the next year. This suggests a possible upside of 7.9% from the stock's current price. View analysts' price targets for Chemed.

News headlines about CHE stock have trended extremely negative on Sunday, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chemed earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutChemed.

Chemed saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 210,200 shares, a drop of 11.4% from the April 30th total of 237,300 shares. Based on an average daily trading volume, of 131,300 shares, the short-interest ratio is presently 1.6 days. Approximately 1.4% of the company's stock are short sold. View Chemed's Current Options Chain.

Some companies that are related to Chemed include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), R1 RCM (RCM), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), Home Depot (HD), Altria Group (MO), Target (TGT), Verizon Communications (VZ), AbbVie (ABBV), Boeing (BA), CVS Health (CVS), Chevron (CVX) and Johnson & Johnson (JNJ).

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.49%), Acadian Asset Management LLC (3.26%), State Street Corp (2.57%), Riverbridge Partners LLC (2.27%), Invesco Ltd. (2.15%) and Fisher Asset Management LLC (1.84%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs. View institutional ownership trends for Chemed.

CHE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Invesco Ltd., Federated Hermes Inc., Wells Fargo & Company MN, BNP Paribas Arbitrage SA, Principal Financial Group Inc., Boston Trust Walden Corp, and Waddell & Reed Financial Inc.. Company insiders that have sold Chemed company stock in the last year include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Spencer S Lee, and Walter L Krebs. View insider buying and selling activity for Chemed.

CHE stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FDx Advisors Inc., GW&K Investment Management LLC, Deutsche Bank AG, Canada Pension Plan Investment Board, Teacher Retirement System of Texas, TimesSquare Capital Management LLC, and JPMorgan Chase & Co.. View insider buying and selling activity for Chemed.

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHE stock can currently be purchased for approximately $477.16.

Chemed has a market capitalization of $7.57 billion and generates $1.94 billion in revenue each year. The company earns $219.92 million in net income (profit) each year or $13.95 on an earnings per share basis. Chemed employs 16,641 workers across the globe.

The official website for Chemed is www.chemed.com.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.